Abstract
Examine clinical profile of extended-release topiramate (TrokendiXR®) and compare treatment-emergent adverse events (TEAEs) associated with TrokendiXR versus previous immediate-release topiramate (TPM-IR) treatment. Pilot retrospective study analyzing data extracted from medical charts of patients ≥6 years of age prescribed TrokendiXR. TrokendiXR was the most commonly used to prevent migraine. The most common TEAEs recorded during topiramate treatment were cognitive symptoms (word-finding difficulty, attention/concentration difficulty, slowed thinking), paresthesia, gastrointestinal problems and decreased appetite/weight loss. TEAE incidence was significantly (p<0.001) lower during TrokendiXR versus previous TPM-IR treatment. TrokendiXR use and outcomes in clinical practice were consistent with established profile of topiramate. Results supported the potential for better tolerability of TrokendiXR versus TPM-IR.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
